Nigel McCracken
Chief Tech/Sci/R&D Officer bij BERGENBIO ASA
Profiel
Nigel McCracken is currently the Chief Scientific Officer at BerGenBio ASA and the Chief Operating Officer at Virax Biolabs Group Ltd.
He previously worked as the Executive Director & VP-Translational Medicine at Debiopharm International SA from 2014 to 2019.
He also held a position as COO and Senior VP-Discovery & Early Development at NuCana Plc.
Dr. McCracken received his undergraduate degree from the University of Strathclyde and his graduate degree from King's College London.
Actieve functies van Nigel McCracken
| Bedrijven | Functie | Begin |
|---|---|---|
| BERGENBIO ASA | Chief Tech/Sci/R&D Officer | 01-01-2021 |
| VIRAX BIOLABS GROUP LIMITED | Chief Operating Officer | 01-09-2023 |
Eerdere bekende functies van Nigel McCracken
| Bedrijven | Functie | Einde |
|---|---|---|
Debiopharm International SA
 Debiopharm International SA Pharmaceuticals: MajorHealth Technology Debiopharm International SA operates as a biopharmaceutical development company with focus on biologics and drug evaluation, licensing and development. It formulates and develops products for the treatment of cancer, endometriosis, uterine fibroids and hepatitis. The company was founded in 1979 and is headquartered in Lausanne, Switzerland. | Director/Board Member | 01-04-2019 |
| NUCANA PLC | Chief Operating Officer | - |
Opleiding van Nigel McCracken
| University of Strathclyde | Undergraduate Degree |
| King's College London | Graduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 3 |
|---|---|
| BERGENBIO ASA | Health Technology |
| NUCANA PLC | Health Technology |
| VIRAX BIOLABS GROUP LIMITED | Finance |
| Bedrijven in privébezit | 1 |
|---|---|
Debiopharm International SA
Debiopharm International SA Pharmaceuticals: MajorHealth Technology Debiopharm International SA operates as a biopharmaceutical development company with focus on biologics and drug evaluation, licensing and development. It formulates and develops products for the treatment of cancer, endometriosis, uterine fibroids and hepatitis. The company was founded in 1979 and is headquartered in Lausanne, Switzerland. | Health Technology |
